Roche’s MabThera has become the first NICE-approved treatment for two severe forms of vasculitis.
The National Institute for Health and Care Excellence (NICE) has recently granted a stamp of approval for Roche’s MabThera, licensing the drug as a treatment for Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) – two severe forms of vasculitis.
NICE approved the drug – for use in conjunction with glucocorticoids – following the review of clinical trial data that recorded positive safety and efficacy levels when the two were used to tackle the pair of potentially life threatning autoimmune diseases.
MabThera is the first and only drug to be licensed for the treatment of GPA and MPA, and the news was greeted encouragingly by members of the healthcare community: Dr David Jayne, consultant in nephrology and vasculitis at Addenbrookes Hospital, said the recent approval of MabThera would offer patients and physicians in England and Wales “great hope for the future management of these diseases”.
Roche’s NICE approval comes just a few days after Europe’s Committee for Medicinal Products for Human Use recommended a version of MabThera as a potential treatment for common forms of non-Hodgkin lymphoma.